Details of the Drug

General Information of Drug (ID: DMFTPCT)

Drug Name

TSHA-101

Indication

Disease Entry	ICD 11	Status	REF
GM2 gangliosidosis	5C56.00	Phase 1/2	[1]
------------------------------------------------------------------------------------

Drug Type

Gene therapy

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Beta-hexosaminidase subunit alpha (HEXA)	TTJI5JW	HEXA_HUMAN	Not Available	[1]
Beta-hexosaminidase subunit beta (HEXB)	TTKIBKM	HEXB_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04798235) Phase 1/2, Open-Label Clinical Study to Evaluate the Safety and Efficacy of Intrathecal TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis. U.S.National Institutes of Health.